A detailed history of Parkman Healthcare Partners LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 464,048 shares of BCRX stock, worth $3.51 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
464,048
Previous 400,448 15.88%
Holding current value
$3.51 Million
Previous $2.47 Million 42.52%
% of portfolio
0.5%
Previous 0.37%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.41 - $8.69 $407,676 - $552,684
63,600 Added 15.88%
464,048 $3.53 Million
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $1.65 Million - $2.72 Million
400,448 New
400,448 $2.47 Million
Q2 2022

Aug 12, 2022

SELL
$7.89 - $17.88 $3.76 Million - $8.53 Million
-476,978 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$11.56 - $19.76 $889,854 - $1.52 Million
76,977 Added 19.24%
476,978 $7.76 Million
Q4 2021

Feb 11, 2022

BUY
$11.18 - $15.46 $3.33 Million - $4.61 Million
298,040 Added 292.31%
400,001 $5.54 Million
Q3 2021

Nov 12, 2021

SELL
$14.21 - $17.65 $3.55 Million - $4.41 Million
-250,000 Reduced 71.03%
101,961 $1.47 Million
Q2 2021

Aug 13, 2021

BUY
$9.5 - $17.24 $1.02 Million - $1.85 Million
107,281 Added 43.85%
351,961 $5.57 Million
Q1 2021

May 14, 2021

SELL
$7.37 - $13.61 $2.16 Million - $4 Million
-293,690 Reduced 54.55%
244,680 $2.49 Million
Q4 2020

Feb 12, 2021

SELL
$3.37 - $8.61 $884,186 - $2.26 Million
-262,370 Reduced 32.77%
538,370 $4.01 Million
Q3 2020

Nov 13, 2020

SELL
$3.43 - $5.53 $342,547 - $552,270
-99,868 Reduced 11.09%
800,740 $2.75 Million
Q2 2020

Aug 13, 2020

SELL
$1.9 - $5.61 $180,500 - $532,950
-95,000 Reduced 9.54%
900,608 $4.29 Million
Q1 2020

May 15, 2020

SELL
$1.6 - $4.11 $232,966 - $598,432
-145,604 Reduced 12.76%
995,608 $1.99 Million
Q4 2019

Feb 13, 2020

BUY
$1.59 - $3.45 $1.81 Million - $3.94 Million
1,141,212 New
1,141,212 $3.94 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Parkman Healthcare Partners LLC Portfolio

Follow Parkman Healthcare Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.